Oncology stops at the blood-brain barrier.
Reglagene is developing an oral therapy for CNS oncology: the primary tumor and the metastases, including in the brain.
Cancer that reaches the brain has almost nothing that works.
RGN6024 is an oral, twice-daily small molecule built to cross the blood-brain barrier by design. It is developed to treat the primary tumor and the metastases it spreads, including those that reach the brain. Our efficacy models to date are in glioblastoma and in small cell lung cancer; the same approach applies to other solid tumors that seed the brain and are susceptible to a microtubule destabilizer.
How RGN6024 works
Crosses the blood-brain barrier by design.
Half the size of the FDA-approved tubulin targeting therapies, our therapy has low molecular weight which makes it easier to pass into cells and into the brain.
Tumor in the brain. Dosed by mouth. Signal reduced to near background.
In the BT-142 intracranial glioma model, twice-daily oral RGN6024 reduced bioluminescent tumor signal by 98% versus vehicle (p < 0.0001), with 100% survival. Published in Molecular Cancer Therapeutics 2025;24(8):1129-1144.
Not removed by the efflux pump.
Efflux pumps sit in the brain and remove toxins (or medicines). Reglagene’s medicine is not recognized by efflux pumps. It stays in the brain and keeps attacking the tumor.
Latest News
